SARS-CoV-2 antibody prevalence and correlates of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June–October 2020

Coyer, Liza; Boyd, Anders; Schinkel, Janke; Agyemang, Charles; Galenkamp, Henrike; Koopman, Anitra D.M.; Leenstra, Tjalling; Charante, Eric P. Moll van; Born, Bert‐Jan H. van den; Lok, Anja; Verhoeff, Arnoud P.; Zwinderman, Aeilko H.; Jurriaans, Suzanne; Vught, Lonneke A. van; Stronks, Karien; Prins, Maria

doi:10.1136/bmjopen-2021-052752

Cited by 18 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the same year, higher seropositivity rates were observed in New York City (May–July 2020; 18+ years; 23.6% [ 10 ] and June–October 2020; 18+ years; 24.3% [ 11 ]), Saudi-Arabia (May–July 2020; 18+ years; 19.3%) [ 12 ], Ireland (June–July 2020; 18+ years; 12.6%) [ 13 ], and Mexico (August–November 2020; 20–39 (27.9%), 40–59 (27.8%) and 60+ (18.6%) years) [ 14 ]. Similar rates were observed in Ethiopia (June–July 2020; 15+ years, 3.2%) [ 15 ], England (April–September 2020; 18–65 years; 5.9%) [ 16 ], Amsterdam, the Netherlands (June and October 2020; 18–70 years, 9.4%) [ 17 ], Germany (May–June 2020; 18+ years; 11.3%) [ 10 ], and the United States (July 2020 (3.5%), December 2020 (11.5%); 16+ years) [ 18 ]. In Australia, between April and June 2020, the seropositivity rate among 20 year olds and above was lower than 1% [ 19 ].…”

Section: Discussionsupporting

confidence: 69%

Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021

et al. 2022

View full text Add to dashboard Cite

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Israel in February 2020 and spread from then. In December 2020, the FDA approved an emergency use authorization of the Pfizer-BioNTech vaccine, and on 20 December, an immunization campaign began among adults in Israel. We characterized seropositivity for IgG anti-spike antibodies against SARS-CoV-2 between January 2020 and July 2021, before and after the introduction of the vaccine in Israel among adults. We tested 9520 serum samples, collected between January 2020 and July 2021. Between January and August 2020, seropositivity rates were lower than 5.0%; this rate increased from September 2020 (6.3%) to April 2021 (84.9%) and reached 79.1% in July 2021. Between January and December 2020, low socio-economic rank was an independent, significant correlate for seropositivity. Between January and July 2021, the 40.00–64.99-year-old age group, Jews and others, and residents of the Northern district were significantly more likely to be seropositive. Our findings indicate a slow, non-significant increase in the seropositivity rate to SARS-CoV-2 between January and December 2020. Following the introduction of the Pfizer-BioNTech vaccine in Israel, a significant increase in seropositivity was observed from January until April 2021, with stable rates thereafter, up to July 2021.

show abstract

Section: Discussionsupporting

confidence: 69%

Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Additionally, we found strong associations with being born outside the Netherlands and not using the app. If national app usage trends reflect those found in our sample, this would be worrisome given that previous studies in Amsterdam and internationally have shown that some ethnic minority groups are disproportionately affected by SARS-CoV-2 [31][32][33][34][35][36]. Cultural differences or distrust in the authorities may underlie this observation, but other more practical issues might be important as well.…”

Section: Comparison With Prior Workmentioning

confidence: 53%

“…Unfortunately, the routine data used in this study do not contain information on language skills or parental birth country, and thus we cannot investigate app use among second-generation immigrants. Further research in this group is therefore needed to reduce health inequalities between ethnic groups [ 35 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

Factors Associated With Using the COVID-19 Mobile Contact-Tracing App Among Individuals Diagnosed With SARS-CoV-2 in Amsterdam, the Netherlands: Observational Study

Ritsema¹,

Bosdriesz²,

Leenstra³

et al. 2022

JMIR Mhealth Uhealth

Self Cite

View full text Add to dashboard Cite

Background Worldwide, efforts are being made to stop the COVID-19 pandemic caused by SARS-CoV-2. Contact tracing and quarantining are key in limiting SARS-CoV-2 transmission. Mathematical models have shown that the time between infection, isolation of cases, and quarantining of contacts are the most important components that determine whether the pandemic can be controlled. Mobile contact-tracing apps could accelerate the tracing and quarantining of contacts, including anonymous contacts. However, real-world observational data on the uptake and determinants of contact-tracing apps are limited. Objective The aim of this paper is to assess the use of a national Dutch contact-tracing app among notified cases diagnosed with SARS-CoV-2 infection and investigate which characteristics are associated with the use of the app. Methods Due to privacy regulations, data from the app could not be used. Instead, we used anonymized SARS-CoV-2 routine contact-tracing data collected between October 28, 2020, and February 26, 2021, in the region of Amsterdam, the Netherlands. Complete case logistic regression analysis was performed to identify which factors (age, gender, country of birth, municipality, number of close contacts, and employment in either health care or education) were associated with using the app. Age and number of close contacts were modelled as B-splines due to their nonlinear relationship. Results Of 29,766 SARS-CoV-2 positive cases, 4824 (16.2%) reported app use. Median age of cases was 41 (IQR 29-55) years, and 46.7% (n=13,898) were male. In multivariable analysis, males (adjusted odds ratio [AOR] 1.11, 95% CI 1.04-1.18) and residents of municipalities surrounding Amsterdam were more likely to use the app (Aalsmeer AOR 1.34, 95% CI 1.13-1.58; Ouder-Amstel AOR 1.96, 95% CI 1.54-2.50), while people born outside the Netherlands, particularly those born in non-Western countries (AOR 0.33, 95% CI 0.30-0.36), were less likely to use the app. Odds of app use increased with age until the age of 58 years and decreased sharply thereafter (P<.001). Odds of app use increased with number of contacts, peaked at 8 contacts, and then decreased (P<.001). Individuals working in day care, home care, and elderly nursing homes were less likely to use the app. Conclusions Contact-tracing app use among people with confirmed SARS-CoV-2 infection was low in the region of Amsterdam. This diminishes the potential impact of the app by hampering the ability to warn contacts. Use was particularly low among older people, people born outside the Netherlands, and people with many contacts. Use of the app was also relatively low compared to those from some other European countries, some of which had additional features beyond contact tracing, making them potentially more appealing. For the Dutch contact-tracing app to have an impact, uptake needs to be higher; therefore, investing more into promotional efforts and additional features could be considered.

show abstract

“…However, the studies in Africa with lower specificity of IgG and IgM to predicting COVID-19 diagnosis. These results may be related to the intensity of immune response between different races to produce antibodies against the SARS-CoV-2 infection ( 35 , 36 ). Previous study has shown that Hispanics and Blacks had higher rates of SARS-CoV-2 antibodies than Whites, indicating that SARS-CoV-2 spread disproportionately in racial and ethnic minorities during the COVID-19 pandemic ( 37 , 38 ).…”

Section: Discussionmentioning

confidence: 99%

Auxiliary Screening COVID-19 by Serology

Pan

Kaminga

Chen

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundThe 2019 novel coronavirus (COVID-19) pandemic remains rampant in many countries/regions. Improving the positive detection rate of COVID-19 infection is an important measure for control and prevention of this pandemic. This meta-analysis aims to systematically summarize the current characteristics of the auxiliary screening methods by serology for COVID-19 infection in real world.MethodsWeb of Science, Cochrane Library, Embase, PubMed, CNKI, and Wangfang databases were searched for relevant articles published prior to May 1st, 2022. Data on specificity, sensitivity, positive/negative likelihood ratio, area under curve (AUC), and diagnostic odds ratio (dOR) were calculated purposefully.ResultsSixty-two studies were included with 35,775 participants in the meta-analysis. Among these studies, the pooled estimates for area under the summary receiver operator characteristic of IgG and IgM to predicting COVID-19 diagnosis were 0.974 and 0.928, respectively. The IgG dOR was 209.78 (95% CI: 106.12 to 414.67). The IgM dOR was 78.17 (95% CI: 36.76 to 166.25).ConclusionOur findings support serum-specific antibody detection may be the main auxiliary screening methods for COVID-19 infection in real world.

show abstract

SARS-CoV-2 antibody prevalence and correlates of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June–October 2020

Cited by 18 publications

References 38 publications

Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021

Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021

Factors Associated With Using the COVID-19 Mobile Contact-Tracing App Among Individuals Diagnosed With SARS-CoV-2 in Amsterdam, the Netherlands: Observational Study

Auxiliary Screening COVID-19 by Serology

Contact Info

Product

Resources

About